Keloid and Hypertrophic Scar Differential Diagnoses

  • Author: Brian Berman, MD, PhD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: May 14, 2010
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Brian Berman, MD, PhD  Professor, Departments of Dermatology and Internal Medicine, University of Miami School of Medicine

Brian Berman, MD, PhD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Graceway Fee to Department Consulting; 3M Fee to Department Consulting; 3M Honoraria Speaking and teaching; Beilis Fee to Department Consulting; UCB Fee to Department Consulting; Shionogi None Consulting; Astellas Review panel membership; Warner-Chilcott Honoraria Speaking and teaching; Orthologic Fee to Department Consulting; Obagi Medical Fee to Department Consulting

Coauthor(s)

Whitney Valins  Clinical Research Fellow, Skin Research Group, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine

Disclosure: Nothing to disclose.

Sadegh Amini, MD  Senior Clinical Research Fellow, Skin Research Group, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami

Sadegh Amini, MD is a member of the following medical societies: American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, and International Society of Dermatology

Disclosure: Nothing to disclose.

Martha H Viera, MD  Senior Clinical Research Fellow, Department of Dermatology and Cutaneous Surgery, University of Miami

Martha H Viera, MD is a member of the following medical societies: American Medical Association and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Kathryn Schwarzenberger, MD  Associate Professor of Medicine, Division of Dermatology, University of Vermont College of Medicine; Consulting Staff, Division of Dermatology, Fletcher Allen Health Care

Kathryn Schwarzenberger, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, American Dermatological Association, Dermatology Foundation, Medical Dermatology Society, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

John G Albertini, MD  Consulting Staff, Dermatologic Surgery, The Skin Surgery Center; Program Director, ACGME accredited Fellowship in Procedural Dermatology

John G Albertini, MD is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Kischer CW, Brody GS. Structure of the collagen nodule from hypertrophic scars and keloids. Scan Electron Microsc. 1981;371-6. [Medline].

  2. Berman B, Flores F. Interferons. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, Pa: WB Saunders; 2001:339-57.

  3. Torkian BA, Yeh AT, Engel R, Sun CH, Tromberg BJ, Wong BJ. Modeling aberrant wound healing using tissue-engineered skin constructs and multiphoton microscopy. Arch Facial Plast Surg. May-Jun 2004;6(3):180-7. [Medline].

  4. Conejo-Mir JS, Corbi R, Linares M. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol. Dec 1998;39(6):1039-40. [Medline].

  5. Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol. Feb 2008;47(2):183-6. [Medline].

  6. Wittenberg GP, Fabian BG, Bogomilsky JL, et al. Prospective, single-blind, randomized, controlled study to assess the efficacy of the 585-nm flashlamp-pumped pulsed-dye laser and silicone gel sheeting in hypertrophic scar treatment. Arch Dermatol. Sep 1999;135(9):1049-55. [Medline].

  7. al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol. Jul 1996;35(7):515-7. [Medline].

  8. Davison SP, Mess S, Kauffman LC, Al-Attar A. Ineffective treatment of keloids with interferon alpha-2b. Plast Reconstr Surg. Jan 2006;117(1):247-52. [Medline].

  9. Pittet B, Rubbia-Brandt L, Desmoulière A, et al. Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg. May 1994;93(6):1224-35. [Medline].

  10. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol. Mar 2005;52(3 Pt 1):474-9. [Medline].

  11. Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg. Jan 2004;30(1):54-6; discussion 56-7. [Medline].

  12. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg. Jul 2006;32(7):907-15. [Medline].

  13. Manuskiatti W, Fitzpatrick RE, Goldman MP. Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laser. J Am Acad Dermatol. Oct 2001;45(4):557-65. [Medline].

  14. Goldan O, Weissman O, Regev E, Haik J, Winkler E. Treatment of postdermabrasion facial hypertrophic and keloid scars with intralesional 5-Fluorouracil injections. Aesthetic Plast Surg. Mar 2008;32(2):389-92. [Medline].

  15. Saray Y, Gulec AT. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int J Dermatol. Sep 2005;44(9):777-84. [Medline].

  16. Muszynska A, Palka J, Gorodkiewicz E. The mechanism of daunorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis. Exp Toxicol Pathol. May 2000;52(2):149-55. [Medline].

  17. Muszynska A, Palka J, Wolczynski S. Doxorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis. Pol J Pharmacol. Mar-Apr 1998;50(2):151-7. [Medline].

  18. Muszynska A, Wolczynski S, Palka J. The mechanism for anthracycline-induced inhibition of collagen biosynthesis. Eur J Pharmacol. Jan 5 2001;411(1-2):17-25. [Medline].

  19. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg. Jan 2001;27(1):23-7. [Medline].

  20. Bodokh I, Brun P. [Treatment of keloid with intralesional bleomycin]. Ann Dermatol Venereol. 1996;123(12):791-4. [Medline].

  21. Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen. Jan-Feb 2007;15(1):122-33. [Medline].

  22. Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg. Aug 2006;32(8):1023-9; discussion 1029-30. [Medline].

  23. Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol. Mar 2008;7(1):43-9. [Medline].

  24. Copcu E, Sivrioglu N, Oztan Y. Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil. Jan-Feb 2004;25(1):1-7. [Medline].

  25. D'Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology. 2002;204(1):60-2. [Medline].

  26. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. Mar 1995;108 (Pt 3):985-1002. [Medline].

  27. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg. Aug 1996;37(2):167-9. [Medline].

  28. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol. Jul-Aug 2008;74(4):343-8. [Medline].

  29. Janssen de Limpens AM. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol. Sep 1980;103(3):319-23. [Medline].

  30. Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol. Nov 1988;14(11):1275-6. [Medline].

  31. Martin-Garcia RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg. Nov 2005;31(11 Pt 1):1394-8. [Medline].

  32. Smith P, Mosiello G, Deluca L, Ko F, Maggi S, Robson MC. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res. Apr 1999;82(2):319-23. [Medline].

  33. Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai. Jul 2007;90(7):1363-7. [Medline].

  34. Kim A, DiCarlo J, Cohen C, et al. Are keloids really "gli-loids"?: High-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol. Nov 2001;45(5):707-11. [Medline].

  35. Ong CT, Khoo YT, Mukhopadhyay A, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. May 2007;16(5):394-404. [Medline].

  36. Hu D, Hughes MA, Cherry GW. Topical tamoxifen--a potential therapeutic regime in treating excessive dermal scarring?. Br J Plast Surg. Sep 1998;51(6):462-9. [Medline].

  37. Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg. Apr-Jun 2001;3(2):111-4. [Medline].

  38. Zhibo X, Miaobo Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg. Sep 2008;61(9):1128-9. [Medline].

  39. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. Nov 2009;124(5):275e-7e. [Medline].

  40. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. May 2009;33(3):409-412. [Medline].

  41. Venus MR. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. Jan 2007;119(1):423-4; author reply 424. [Medline].

  42. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. Jul 2002;110(1):177-83; discussion 184-6. [Medline].

  43. McGrouther DA, et al. A Double Blind, Within Patient, Placebo Controlled Trial to Confirm the Efficacy of Juvista (Avotermin) in Conjunction With Scar Revision Surgery for the Improvement of Disfiguring Scars. ClinicalTrials.gov Identifier: NCT00742443. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00742443. Accessed November 3, 2008.

  44. Bush J, et al. A Double Blind, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Subjects Undergoing Excision of Benign Head and Neck Naevi. ClinicalTrials.gov Identifier: NCT00656227. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00656227. Accessed November 3, 2008.

  45. Bush J, et al. A Double-Blind, Placebo-Controlled, Randomised Dose Ranging Trial to Investigate the Efficacy of Two Different Dosing Regimens of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT00629811. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00629811. Accessed November 3, 2008.

  46. Gilbert P, et al. A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance in Patients Undergoing Bilateral Reduction Mammaplasty. ClinicalTrials.gov Identifier: NCT00432328. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00432328. Accessed November 3, 2008.

  47. McCollum P, et al. A Dose Response Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins Following Bilateral Varicose Vein Removal. ClinicalTrials.gov Identifier: NCT00430326. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00430326. Accessed November 3, 2008.

  48. McGrouther, DA et al. A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery. ClinicalTrials.gov Identifier: NCT00432211. Available at http://www.clinicaltrials.gov/ct2/show/NCT00432211. Accessed November 3, 2008.

  49. Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg. Feb 2006;32(2):193-7. [Medline].

  50. Draelos ZD. The ability of onion extract gel to improve the cosmetic appearance of postsurgical scars. J Cosmet Dermatol. Jun 2008;7(2):101-4. [Medline].

  51. Ho WS, Ying SY, Chan PC, Chan HH. Use of onion extract, heparin, allantoin gel in prevention of scarring in chinese patients having laser removal of tattoos: a prospective randomized controlled trial. Dermatol Surg. Jul 2006;32(7):891-6. [Medline].

  52. Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol Surg. Nov 2008;34(11):1507-14. [Medline].

  53. Hosnuter M, Payasli C, Isikdemir A, Tekerekoglu B. The effects of onion extract on hypertrophic and keloid scars. J Wound Care. Jun 2007;16(6):251-4. [Medline].

  54. Perez OA, Viera MH, Patel J, et al. A Prospective, Randomized, Invetigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars. (Unpublished data).

  55. Beckenstein MS, Kuniaki T, Matarasso A. The effect of Scarguard on collagenase levels using a full-thickness epidermal model. Aesthet Surg J. Nov-Dec 2004;24(6):542-6. [Medline].

  56. Eisen D. A pilot study to evaluate the efficacy of Scarguard in the prevention of scars. Internet J Dermatol. 2004;5(2).

  57. Palmieri B, Gozzi G, Palmieri G. Vitamin E added silicone gel sheets for treatment of hypertrophic scars and keloids. Int J Dermatol. Jul 1995;34(7):506-9. [Medline].

  58. Baumann LS, Spencer J. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg. Apr 1999;25(4):311-5. [Medline].

  59. Jenkins M, Alexander JW, MacMillan BG, Waymack JP, Kopcha R. Failure of topical steroids and vitamin E to reduce postoperative scar formation following reconstructive surgery. J Burn Care Rehabil. Jul-Aug 1986;7(4):309-12. [Medline].

  60. Garg MK, Weiss P, Sharma AK, et al. Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation. Radiother Oncol. Nov 2004;73(2):233-6. [Medline].

  61. Berman B, Viera MH, Amini S, Huo R, Jones IS. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg. Jul 2008;19(4):989-1006. [Medline].

  62. Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol. Jun 2004;50(6):850-3. [Medline].

  63. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. Aug 20 2002;99(17):11205-10. [Medline]. [Full Text].

  64. Salem A, Assaf M, Helmy A, et al. Role of vascular endothelial growth factor in keloids: a clinicopathologic study. Int J Dermatol. Oct 2009;48(10):1071-7. [Medline].

  65. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A. Feb 18 2003;100(4):1844-8. [Medline]. [Full Text].

  66. Steinbrech DS, Mehrara BJ, Chau D, et al. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. May 1999;42(5):514-9; discussion 519-20. [Medline].

  67. Le AD, Zhang Q, Wu Y, et al. Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis. Cells Tissues Organs. 2004;176(1-3):87-94. [Medline].

  68. Zhang GY, Yi CG, Li X, et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res. Apr 2008;300(4):177-84. [Medline].

  69. Tiede S, Ernst N, Bayat A, Paus R, Tronnier V, Zechel C. Basic fibroblast growth factor: a potential new therapeutic tool for the treatment of hypertrophic and keloid scars. Ann Anat. Jan 2009;191(1):33-44. [Medline].

  70. Xie JL, Bian HN, Qi SH, et al. Basic fibroblast growth factor (bFGF) alleviates the scar of the rabbit ear model in wound healing. Wound Repair Regen. Jul-Aug 2008;16(4):576-81. [Medline].

  71. Ono I, Akasaka Y, Kikuchi R, et al. Basic fibroblast growth factor reduces scar formation in acute incisional wounds. Wound Repair Regen. Sep-Oct 2007;15(5):617-23. [Medline].

  72. Naim R, Naumann A, Barnes J, et al. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. Aesthetic Plast Surg. Mar 2008;32(2):346-52. [Medline].

  73. Ono I, Yamashita T, Hida T, et al. Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J Surg Res. Jul 2004;120(1):47-55. [Medline].

  74. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. Mar 2003;4(3):202-12. [Medline].

  75. Viera MH, Amini S, Konda S, Berman B. Do postsurgical interventions optimize ultimate scar cosmesis. G Ital Dermatol Venereol. Jun 2009;144(3):243-57. [Medline].

  76. Juvidex. Products in Development. Available at www.renovo.com. Accessed March 15, 2010.

  77. A Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of Two Concentrations of Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites Using Different Dosing Regimes. ClinicalTrials.gov Identifier: NCT00664352. clinicaltrials.gov. Available at http://clinicaltrials.gov/ NCT00664352. Accessed March 15, 2010.

  78. Hayashi T, Nishihira J, Koyama Y, Sasaki S, Yamamoto Y. Decreased prostaglandin E2 production by inflammatory cytokine and lower expression of EP2 receptor result in increased collagen synthesis in keloid fibroblasts. J Invest Dermatol. May 2006;126(5):990-7. [Medline].

  79. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. Jun 1994;107(2):179-85. [Medline].

  80. Miyazawa K, Hamano S, Ujiie A. Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture. Br J Pharmacol. Jun 1996;118(4):915-22. [Medline]. [Full Text].

  81. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. Oct 1992;60(2):91-6. [Medline].

  82. Topol BM, Lewis VL Jr, Benveniste K. The use of antihistamine to retard the growth of fibroblasts derived from human skin, scar, and keloid. Plast Reconstr Surg. Aug 1981;68(2):227-32. [Medline].

  83. Venugopal J, Ramakrishnan M, Habibullah CM, Babu M. The effect of the anti-allergic agent avil on abnormal scar fibroblasts. Burns. May 1999;25(3):223-8. [Medline].

  84. Shigeki S, Murakami T, Yata N, Ikuta Y. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg. Jun 1997;31(2):151-8. [Medline].

  85. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem. Oct 1994;116(4):892-7. [Medline].

  86. Schafer A, Chovanova Z, Muchova J, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother. Jan 2006;60(1):5-9. [Medline].

  87. Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol. Sep 2009;9(10):1145-9. [Medline].

  88. Grimm T, Schafer A, Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med. Mar 15 2004;36(6):811-22. [Medline].

  89. Grimm T, Chovanova Z, Muchova J, et al. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond). Jan 2006;3:1. [Medline].

  90. Matsumori A. Treatment options in myocarditis: what we know from experimental data and how it translates to clinical trials. Herz. Sep 2007;32(6):452-6. [Medline].

  91. Lee DA. Antifibrosis agents and glaucoma surgery. Invest Ophthalmol Vis Sci. Oct 1994;35(11):3789-91. [Medline].

  92. Stewart CE 4th, Kim JY. Application of mitomycin-C for head and neck keloids. Otolaryngol Head Neck Surg. Dec 2006;135(6):946-50. [Medline].

  93. Simman R, Alani H, Williams F. Effect of mitomycin C on keloid fibroblasts: an in vitro study. Ann Plast Surg. 2003;50:71-76. [Medline].

  94. Bailey JN, Waite AE, Clayton WJ, Rustin MH. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. Br J Dermatol. Apr 2007;156(4):682-6. [Medline].

  95. Talmi YP, Orenstein A, Wolf M, Kronenberg J. Use of mitomycin C for treatment of keloid: a preliminary report. Otolaryngol Head Neck Surg. Apr 2005;132(4):598-601. [Medline].

  96. Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg. May-Jun 2005;7(3):172-5. [Medline].

  97. AZX100 Mode of Action. Available at http://www.capstonethx.com/researchdevelopment/AZX100modeofaction.php. Accessed MARch 15, 2010.

  98. Parish JL, Rhouth HB, Parish LC. Keloids: Innovative Therapy. Poster P3513 presented a the 68th Annual Meeting of American Academy of Dermatology. March 5-9, 2010, Miami, FL. J Am Acad Dermatol. Mar 2010;62(3 Supp):AB147.

  99. 101. A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids. ClinicalTrials.gov Identifier: NCT00825916. clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00825916. Accessed March 15, 2010.

  100. 102. A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids. ClinicalTrials.gov Identifier: NCT00892723. clinicaltrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00892723.. Accessed March 15, 2010.

  101. Berman B, Frankel S, Villa AM, Ramirez CC, Poochareon V, Nouri K. Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. Dermatol Surg. Nov 2005;31(11 Pt 1):1399-403. [Medline].

  102. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol. Oct 2002;47(4 Suppl):S209-11. [Medline].

  103. Alster T. Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. Jan 2003;29(1):25-9. [Medline].

  104. Nouri K, Jimenez GP, Harrison-Balestra C, Elgart GW. 585-nm pulsed dye laser in the treatment of surgical scars starting on the suture removal day. Dermatol Surg. Jan 2003;29(1):65-73; discussion 73. [Medline].

  105. Wilgus TA, Bergdall VK, Tober KL, et al. The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing. Am J Pathol. Sep 2004;165(3):753-61. [Medline]. [Full Text].

  106. Conologue TD, Norwood C. Treatment of surgical scars with the cryogen-cooled 595 nm pulsed dye laser starting on the day of suture removal. Dermatol Surg. Jan 2006;32(1):13-20. [Medline].

  107. Manuskiatti W, Wanitphakdeedecha R, Fitzpatrick RE. Effect of pulse width of a 595-nm flashlamp-pumped pulsed dye laser on the treatment response of keloidal and hypertrophic sternotomy scars. Dermatol Surg. Feb 2007;33(2):152-61. [Medline].

  108. Bellew SG, Weiss MA, Weiss RA. Comparison of intense pulsed light to 595-nm long-pulsed pulsed dye laser for treatment of hypertrophic surgical scars: a pilot study. J Drugs Dermatol. Jul-Aug 2005;4(4):448-52. [Medline].

  109. Alam M, Pon K, Van Laborde S, Kaminer MS, Arndt KA, Dover JS. Clinical effect of a single pulsed dye laser treatment of fresh surgical scars: randomized controlled trial. Dermatol Surg. Jan 2006;32(1):21-5. [Medline].

  110. Chiu LL, Sun CH, Yeh AT, et al. Photodynamic therapy on keloid fibroblasts in tissue-engineered keratinocyte-fibroblast co-culture. Lasers Surg Med. Sep 2005;37(3):231-44. [Medline].

  111. Asawanonda P, Khoo LS, Fitzpatrick TB, Taylor CR. UV-A1 for keloid. Arch Dermatol. Mar 1999;135(3):348-9. [Medline].

  112. Sasaki T, Holeyfield KC, Uitto J. Doxorubicin-induced inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures. Relevance to imparied wound healing. J Clin Invest. Dec 1987;80(6):1735-41. [Medline]. [Full Text].

  113. Kang S, et al. The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study. ClinicalTrials.gov Identifier: NCT00476801. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00476801. Accessed November 1, 2008.

  114. Kang S, et al. The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study. ClinicalTrials.gov Identifier: NCT00476697. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00476697. Accessed November 1, 2008.

  115. Choi CP, Kim YI, Lee JW, Lee MH. The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase-1, transforming growth factor-beta1 and type I collagen in human skin fibroblasts. Clin Exp Dermatol. Mar 2007;32(2):180-5. [Medline].

  116. Oiso N, Kawara S, Kawada A. The effectiveness of narrowband ultraviolet B on hypertrophic scar in a patient having an isomorphic phenomenon and vitiligo. J Eur Acad Dermatol Venereol. May 15 2008;[Medline].

  117. Varga J, Diaz-Perez A, Rosenbloom J, Jimenez SA. PGE2 causes a coordinate decrease in the steady state levels of fibronectin and types I and III procollagen mRNAs in normal human dermal fibroblasts. Biochem Biophys Res Commun. Sep 30 1987;147(3):1282-8. [Medline].

  118. Cartier H. Use of intense pulsed light in the treatment of scars. J Cosmet Dermatol. Jan 2005;4(1):34-40. [Medline].

  119. Erol OO, Gurlek A, Agaoglu G, Topcuoglu E, Oz H. Treatment of hypertrophic scars and keloids using intense pulsed light (IPL). Aesthetic Plast Surg. Nov 2008;32(6):902-9. [Medline].

 
Previous
Next
 
Clawlike outline of a keloid. Courtesy of Dirk M. Elston, MD.
Keloid. Courtesy of Dirk M. Elston, MD.
Keloid. Courtesy of Dirk M. Elston, MD.
Keloid. Courtesy of Dirk M. Elston, MD.
Histology of keloid demonstrating central zone of hyalinized collagen (hematoxylin and eosin stain). Courtesy of Dirk M. Elston, MD.
Histology of keloid demonstrating thick hyalinized collagen bundles (hematoxylin and eosin stain). Courtesy of Dirk M. Elston, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.